93 related articles for article (PubMed ID: 23638744)
21. Development and characterization of anti-renal cell carcinoma x antichelate bispecific monoclonal antibodies for two-phase targeting of renal cell carcinoma.
Kranenborg MH; Boerman OC; Oosterwijk-Wakka JC; de Weijert MC; Corstens FH; Oosterwijk E
Cancer Res; 1995 Dec; 55(23 Suppl):5864s-5867s. PubMed ID: 7493361
[TBL] [Abstract][Full Text] [Related]
22. Indocyanine Green-Loaded Nanobubbles Targeting Carbonic Anhydrase IX for Multimodal Imaging of Renal Cell Carcinoma.
Zhong C; Chen J; Ling Y; Liu D; Xu J; Wang L; Ge C; Jiang Q
Int J Nanomedicine; 2023; 18():2757-2776. PubMed ID: 37250472
[TBL] [Abstract][Full Text] [Related]
23. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
van Schaijk FG; Oosterwijk E; Molkenboer-Kuenen JD; Soede AC; McBride BJ; Goldenberg DM; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2005 Mar; 46(3):495-501. PubMed ID: 15750164
[TBL] [Abstract][Full Text] [Related]
24. [Molecular detection of circulating cancer cells in patients with renal cell carcinoma].
Uemura H
Hinyokika Kiyo; 1999 Aug; 45(8):571-5. PubMed ID: 10500965
[TBL] [Abstract][Full Text] [Related]
25. Carbonic anhydrase 10 functions as a tumor suppressor in renal cell carcinoma and its methylation is a risk factor for survival outcome.
Li Q; Zhang L; Zhang Z; Fan Y; Zhang Q
Urol Oncol; 2022 Apr; 40(4):168.e1-168.e9. PubMed ID: 34980544
[TBL] [Abstract][Full Text] [Related]
26. The pathway to biomarker discovery: carbonic anhydrase IX and the prediction of immune responsiveness.
Panelli MC; Wang E; Marincola FM
Clin Cancer Res; 2005 May; 11(10):3601-3. PubMed ID: 15897553
[No Abstract] [Full Text] [Related]
27. Advances in immune-based therapies of renal cell carcinoma.
Lam JS; Belldegrun AS; Figlin RA
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1081-96. PubMed ID: 15606335
[TBL] [Abstract][Full Text] [Related]
28. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
29. Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data.
McDermott DF; George DJ
Cancer Treat Rev; 2010 May; 36(3):216-23. PubMed ID: 20116176
[TBL] [Abstract][Full Text] [Related]
30. Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma.
Oosterwijk-Wakka JC; Boerman OC; Mulders PF; Oosterwijk E
Int J Mol Sci; 2013 May; 14(6):11402-23. PubMed ID: 23759990
[TBL] [Abstract][Full Text] [Related]
31. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.
Lam JS; Shvarts O; Leppert JT; Figlin RA; Belldegrun AS
J Urol; 2005 Jun; 173(6):1853-62. PubMed ID: 15879764
[TBL] [Abstract][Full Text] [Related]
32. New therapeutic developments in renal cell cancer.
Prenen H; Gil T; Awada A
Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971
[TBL] [Abstract][Full Text] [Related]
33. Durable Response to Treatment With Combination Radiotherapy and High-dose Interleukin-2 in Metastatic Chromophobe Variant Renal Cell Carcinoma.
Merriman J; Tward J; Albertson D; Dechet C; Agarwal N
J Immunother; 2016; 39(2):101-3. PubMed ID: 26849079
[TBL] [Abstract][Full Text] [Related]
34. Radiotherapy for renal-cell carcinoma.
De Meerleer G; Khoo V; Escudier B; Joniau S; Bossi A; Ost P; Briganti A; Fonteyne V; Van Vulpen M; Lumen N; Spahn M; Mareel M
Lancet Oncol; 2014 Apr; 15(4):e170-7. PubMed ID: 24694640
[TBL] [Abstract][Full Text] [Related]
35. Noninvasive determination of renal tumor histology utilizing molecular imaging.
Gorin MA; Rowe SP; Allaf ME
Urol Oncol; 2016 Dec; 34(12):525-528. PubMed ID: 27888980
[No Abstract] [Full Text] [Related]
36. Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach.
Siva S; Kothari G; Muacevic A; Louie AV; Slotman BJ; Teh BS; Lo SS
Nat Rev Urol; 2017 Sep; 14(9):549-563. PubMed ID: 28631740
[TBL] [Abstract][Full Text] [Related]
37. New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials.
Ciccarese C; Massari F; Santoni M; Heng DY; Sotte V; Brunelli M; Conti A; Cheng L; Lopez-Beltran A; Scarpelli M; Cascinu S; Tortora G; Montironi R
Cancer Treat Rev; 2015 Jul; 41(7):614-22. PubMed ID: 26036356
[TBL] [Abstract][Full Text] [Related]
38. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.
Lamers CH; Sleijfer S; van Steenbergen S; van Elzakker P; van Krimpen B; Groot C; Vulto A; den Bakker M; Oosterwijk E; Debets R; Gratama JW
Mol Ther; 2013 Apr; 21(4):904-12. PubMed ID: 23423337
[TBL] [Abstract][Full Text] [Related]
39. A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors.
Krall N; Pretto F; Decurtins W; Bernardes GJ; Supuran CT; Neri D
Angew Chem Int Ed Engl; 2014 Apr; 53(16):4231-5. PubMed ID: 24623670
[TBL] [Abstract][Full Text] [Related]
40. 'Image and treat': an individualized approach to urological tumors.
Bouchelouche K; Capala J
Curr Opin Oncol; 2010 May; 22(3):274-80. PubMed ID: 20150811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
